Rainer Kraehenmann1, Katrin H Preller2, Milan Scheidegger3, Thomas Pokorny2, Oliver G Bosch4, Erich Seifritz4, Franz X Vollenweider2. 1. Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Neuropsychopharmacology and Brain Imaging, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland. Electronic address: r.kraehenmann@bli.uzh.ch. 2. Department of Neuropsychopharmacology and Brain Imaging, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland. 3. Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Neuropsychopharmacology and Brain Imaging, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich; and Institute for Biomedical Engineering, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland. 4. Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland.
Abstract
BACKGROUND: The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little-known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. METHODS: This study assessed the effects of acute administration of the hallucinogen psilocybin (.16 mg/kg) versus placebo on amygdala reactivity to negative stimuli in 25 healthy volunteers using blood oxygen level-dependent functional magnetic resonance imaging. Mood changes were assessed using the Positive and Negative Affect Schedule and the state portion of the State-Trait Anxiety Inventory. A double-blind, randomized, cross-over design was used with volunteers counterbalanced to receive psilocybin and placebo in two separate sessions at least 14 days apart. RESULTS:Amygdala reactivity to negative and neutral stimuli was lower after psilocybin administration than after placebo administration. The psilocybin-induced attenuation of right amygdala reactivity in response to negative stimuli was related to the psilocybin-induced increase in positive mood state. CONCLUSIONS: These results demonstrate that acute treatment with psilocybin decreased amygdala reactivity during emotion processing and that this was associated with an increase of positive mood in healthy volunteers. These findings may be relevant to the normalization of amygdala hyperactivity and negative mood states in patients with major depression.
RCT Entities:
BACKGROUND: The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little-known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. METHODS: This study assessed the effects of acute administration of the hallucinogen psilocybin (.16 mg/kg) versus placebo on amygdala reactivity to negative stimuli in 25 healthy volunteers using blood oxygen level-dependent functional magnetic resonance imaging. Mood changes were assessed using the Positive and Negative Affect Schedule and the state portion of the State-Trait Anxiety Inventory. A double-blind, randomized, cross-over design was used with volunteers counterbalanced to receive psilocybin and placebo in two separate sessions at least 14 days apart. RESULTS: Amygdala reactivity to negative and neutral stimuli was lower after psilocybin administration than after placebo administration. The psilocybin-induced attenuation of right amygdala reactivity in response to negative stimuli was related to the psilocybin-induced increase in positive mood state. CONCLUSIONS: These results demonstrate that acute treatment with psilocybin decreased amygdala reactivity during emotion processing and that this was associated with an increase of positive mood in healthy volunteers. These findings may be relevant to the normalization of amygdala hyperactivity and negative mood states in patients with major depression.
Authors: Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak Journal: Ther Adv Psychopharmacol Date: 2016-03-18
Authors: Anna Bravermanová; Michaela Viktorinová; Filip Tylš; Tomáš Novák; Renáta Androvičová; Jakub Korčák; Jiří Horáček; Marie Balíková; Inga Griškova-Bulanova; Dominika Danielová; Přemysl Vlček; Pavel Mohr; Martin Brunovský; Vlastimil Koudelka; Tomáš Páleníček Journal: Psychopharmacology (Berl) Date: 2018-01-05 Impact factor: 4.530
Authors: Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths Journal: J Psychopharmacol Date: 2016-11-17 Impact factor: 4.153
Authors: Simon D Brandt; Pierce V Kavanagh; Geraldine Dowling; Brian Talbot; Folker Westphal; Markus R Meyer; Hans H Maurer; Adam L Halberstadt Journal: Drug Test Anal Date: 2016-04-21 Impact factor: 3.345
Authors: Joaquim Soler; Matilde Elices; Alba Franquesa; Steven Barker; Pablo Friedlander; Amanda Feilding; Juan C Pascual; Jordi Riba Journal: Psychopharmacology (Berl) Date: 2015-11-27 Impact factor: 4.530